Literature DB >> 18317666

Therapy effects of green tea in a patient with systemic light-chain amyloidosis.

Derliz Mereles1, Erich E Wanker, Hugo A Katus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18317666     DOI： 10.1007/s00392-008-0649-6

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


× No keyword cloud information.
  15 in total

1.  ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein.

Authors:  Demian F Obregon; Kavon Rezai-Zadeh; Yun Bai; Nan Sun; Huayan Hou; Jared Ehrhart; Jin Zeng; Takashi Mori; Gary W Arendash; Doug Shytle; Terrence Town; Jun Tan
Journal:  J Biol Chem       Date:  2006-04-19       Impact factor: 5.157

2.  Advances in the treatment of amyloidosis.

Authors:  S Vincent Rajkumar; Morie A Gertz
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

3.  Transdermal delivery of (-)-epigallocatechin-3-gallate, a green tea polyphenol, in mice.

Authors:  Joshua D Lambert; Dou Hwan Kim; Ruijin Zheng; Chung S Yang
Journal:  J Pharm Pharmacol       Date:  2006-05       Impact factor: 3.765

4.  Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.

Authors:  Kavon Rezai-Zadeh; Doug Shytle; Nan Sun; Takashi Mori; Huayan Hou; Deborah Jeanniton; Jared Ehrhart; Kirk Townsend; Jin Zeng; David Morgan; John Hardy; Terrence Town; Jun Tan
Journal:  J Neurosci       Date:  2005-09-21       Impact factor: 6.167

5.  Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.

Authors:  M B Pepys; J Herbert; W L Hutchinson; G A Tennent; H J Lachmann; J R Gallimore; L B Lovat; T Bartfai; A Alanine; C Hertel; T Hoffmann; R Jakob-Roetne; R D Norcross; J A Kemp; K Yamamura; M Suzuki; G W Taylor; S Murray; D Thompson; A Purvis; S Kolstoe; S P Wood; P N Hawkins
Journal:  Nature       Date:  2002-05-16       Impact factor: 49.962

Review 6.  Metabolism of green tea catechins: an overview.

Authors:  Wan Yong Feng
Journal:  Curr Drug Metab       Date:  2006-10       Impact factor: 3.731

7.  Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis.

Authors:  Jun Koyama; Patricia A Ray-Sequin; Rodney H Falk
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

8.  M-mode and two-dimensional echocardiographic features in cardiac amyloidosis.

Authors:  A G Siqueira-Filho; C L Cunha; A J Tajik; J B Seward; T T Schattenberg; E R Giuliani
Journal:  Circulation       Date:  1981-01       Impact factor: 29.690

9.  Design, semisynthesis, and evaluation of O-acyl derivatives of (-)-epigallocatechin-3-gallate as antitumor agents.

Authors:  Sandeep Vyas; Manu Sharma; Pritam D Sharma; Tej V Singh
Journal:  J Agric Food Chem       Date:  2007-07-03       Impact factor: 5.279

10.  Eprodisate for the treatment of renal disease in AA amyloidosis.

Authors:  Laura M Dember; Philip N Hawkins; Bouke P C Hazenberg; Peter D Gorevic; Giampaolo Merlini; Irena Butrimiene; Avi Livneh; Olga Lesnyak; Xavier Puéchal; Helen J Lachmann; Laura Obici; Robert Balshaw; Denis Garceau; Wendy Hauck; Martha Skinner
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245
View more
  10 in total

1.  Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

Authors:  Sohsuke Meshitsuka; Sumito Shingaki; Masatoshi Hotta; Miku Goto; Makoto Kobayashi; Yuuichi Ukawa; Yuko M Sagesaka; Yasuyo Wada; Masanori Nojima; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2016-11-04       Impact factor: 2.490

2.  Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis.

Authors:  Derliz Mereles; Sebastian J Buss; Stefan E Hardt; Werner Hunstein; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2010-03-10       Impact factor: 5.460

3.  Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.

Authors:  Kathrin Andrich; Ute Hegenbart; Christoph Kimmich; Niraja Kedia; H Robert Bergen; Stefan Schönland; Erich Wanker; Jan Bieschke
Journal:  J Biol Chem       Date:  2016-12-28       Impact factor: 5.157

4.  The Effect of (-)-Epigallo-catechin-(3)-gallate on Amyloidogenic Proteins Suggests a Common Mechanism.

Authors:  Kathrin Andrich; Jan Bieschke
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

5.  [52 year-old patient with severe heart failure due to multiple myeloma].

Authors:  C Morbach; M Breunig; F Weidemann; M Topp; C Ritter; P Schneider; H Einsele; S Störk; C E Angermann
Journal:  Internist (Berl)       Date:  2009-02       Impact factor: 0.743

Review 6.  Currents concepts on the immunopathology of amyloidosis.

Authors:  Anupama Bhat; Carlo Selmi; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

7.  Diagnostic superiority of a combined assessment of the systolic and early diastolic mitral annular velocities by tissue Doppler imaging for the differentiation of restrictive cardiomyopathy from constrictive pericarditis.

Authors:  Thomas Butz; C Piper; C Langer; M Wiemer; T Kottmann; A Meissner; G Plehn; H J Trappe; D Horstkotte; L Faber
Journal:  Clin Res Cardiol       Date:  2010-01-06       Impact factor: 5.460

8.  Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains.

Authors:  Manuel Hora; Martin Carballo-Pacheco; Benedikt Weber; Vanessa K Morris; Antje Wittkopf; Johannes Buchner; Birgit Strodel; Bernd Reif
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

9.  Green tea extract catechin improves cardiac function in pediatric cardiomyopathy patients with diastolic dysfunction.

Authors:  Junjun Quan; Zhongli Jia; Tiewei Lv; Lei Zhang; Lingjuan Liu; Bo Pan; Jing Zhu; Ira J Gelb; Xupei Huang; Jie Tian
Journal:  J Biomed Sci       Date:  2019-05-08       Impact factor: 8.410

10.  Green tea halts progression of cardiac transthyretin amyloidosis: an observational report.

Authors:  Arnt V Kristen; Stephanie Lehrke; Sebastian Buss; Derliz Mereles; Henning Steen; Philipp Ehlermann; Stefan Hardt; Evangelos Giannitsis; Rupert Schreiner; Uwe Haberkorn; Philipp A Schnabel; Reinhold P Linke; Christoph Röcken; Erich E Wanker; Thomas J Dengler; Klaus Altland; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2012-05-15       Impact factor: 5.460
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.